Filing Details
- Accession Number:
- 0001725160-20-000040
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-25 20:34:14
- Reporting Period:
- 2020-04-07
- Accepted Time:
- 2020-11-25 20:34:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1725160 | Zentalis Pharmaceuticals Inc. | ZNTL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1377952 | Y Anthony Sun | C/O Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue, Suite 2201 New York NY 10018 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-04-07 | 888 | $18.00 | 2,146,568 | No | 4 | P | Direct | |
| Common Stock | Disposition | 2020-11-23 | 13,696 | $46.45 | 2,132,872 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-23 | 1,712 | $47.19 | 2,131,160 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-24 | 5,831 | $46.21 | 2,125,329 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-24 | 5,455 | $46.68 | 2,119,874 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-24 | 100 | $47.56 | 2,119,774 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 974,302 | Indirect | By Essex Group International, LLC |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.99 to $46.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.01 to $47.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.42 to $46.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.42 to $47.09. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
